RÉSUMÉ
We have examined the mechanisms regulating prostacyclin (PGI(2)) synthesis after acute exposure of human umbilical vein endothelial cells (HUVEC) to interleukin-1 alpha (IL-1 alpha). IL-1 alpha evoked an early (30 min) release of PGI(2) and [(3)H]arachidonate that was blocked by the cytosolic phospholipase A(2)alpha (cPLA(2)alpha) inhibitor arachidonyl trifluoromethyl ketone. IL-1 alpha-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2; p42/p44(mapk)) coincided temporally with phosphorylation of cPLA(2)alpha and with the onset of PGI(2) synthesis. The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation. SB-203580 treatment enhanced IL-1 alpha-induced MEK, p42/44(mapk), and cPLA(2)alpha phosphorylation but reduced thrombin-stimulated MEK and p42/44(mapk) activation. IL-1 alpha, but not thrombin, activated Raf-1 as assessed by immune-complex kinase assay, as did SB-203580 alone. These results show that IL-1 alpha causes an acute upregulation of PGI(2) generation in HUVEC, establish a role for the MEK/ERK/cPLA(2)alpha pathway in this early release, and provide evidence for an agonist-specific cross talk between p38(mapk) and p42/44(mapk) that may reflect receptor-specific differences in the signaling elements proximal to MAPK activation.
Sujet(s)
Endothélium vasculaire/enzymologie , Prostacycline/biosynthèse , MAP Kinase Kinase Kinase 1 , Mitogen-Activated Protein Kinase 1/métabolisme , Mitogen-Activated Protein Kinases/métabolisme , Interactions entre récepteurs/physiologie , Acide arachidonique/métabolisme , Acides arachidoniques/pharmacologie , Cellules cultivées , Endothélium vasculaire/cytologie , Antienzymes/pharmacologie , Group IV phospholipases A2 , Hémostatiques/pharmacologie , Humains , Imidazoles/pharmacologie , Interleukine-1/pharmacologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Système de signalisation des MAP kinases/physiologie , Phospholipases A/métabolisme , Phosphorylation , Prostaglandin-endoperoxide synthases/métabolisme , Protein-Serine-Threonine Kinases/métabolisme , Protéines proto-oncogènes c-raf/métabolisme , Pyridines/pharmacologie , Interactions entre récepteurs/effets des médicaments et des substances chimiques , Thrombine/pharmacologie , Veines ombilicales/cytologie , p38 Mitogen-Activated Protein KinasesRÉSUMÉ
The first step in prostacyclin (PGI(2)) synthesis involves the generation of arachidonic acid (AA) from membrane phospholipids mediated by the 85 kDa cytosolic phospholipase A(2) (cPLA(2)alpha). The current study examined the effects of secretory PLA(2)s (sPLA(2)s) on PGI(2) production by human umbilical vein endothelial cells (HUVEC). We demonstrate that exposure of HUVEC to sPLA(2) dose- and time-dependently enhances AA release and PGI(2) generation. sPLA(2)-stimulated AA mobilisation was blocked by AACOCF(3), an inhibitor of cPLA(2)alpha, suggesting cross-talk between the two classes of PLA(2). sPLA(2) induced the phosphorylation of cPLA(2)alpha and enhanced the phosphorylation states of p42/44(mapk), p38(mapk), and JNK, concomitant with elevated AA and PGI(2) release. The MEK inhibitor PD98059 attenuated sPLA(2)-stimulated cPLA(2)alpha phosphorylation and PGI(2) release. These data show that sPLA(2) cooperates with cPLA(2)alpha in a MAPK-dependent manner to regulate PGI(2) generation and suggests that cross-talk between sPLA(2) and cPLA(2)alpha is a physiologically important mechanism for enhancing prostanoid production in endothelial cells.
Sujet(s)
Endothélium vasculaire/métabolisme , Prostacycline/biosynthèse , Phospholipases A/métabolisme , Acide arachidonique/métabolisme , Cellules cultivées , Milieux de culture sans sérum , Relation dose-effet des médicaments , Endothélium vasculaire/cytologie , Endothélium vasculaire/effets des médicaments et des substances chimiques , Activation enzymatique , Antienzymes/pharmacologie , Flavonoïdes/pharmacologie , Group II Phospholipases A2 , Group IV phospholipases A2 , Humains , Isoenzymes/métabolisme , Système de signalisation des MAP kinases/physiologie , Mitogen-Activated Protein Kinases/métabolisme , Phospholipases A/antagonistes et inhibiteurs , Facteurs tempsRÉSUMÉ
Work from this and other laboratories has identified a role for protein tyrosine kinases in interleukin-1 alpha (IL-1 alpha)- and tumor necrosis factor-alpha (TNF-alpha)-induced responses in endothelial cells. In this study, we show that activation of human umbilical vein endothelial cells (HUVEC) by IL-1 alpha leads to increased tyrosine phosphorylation of several proteins including one with a molecular mass of approximately 42 kDa. This protein was identified as p42mapk by Western blot analysis. Tyrosine phosphorylation and catalytic activation of p42mapk by IL-1 alpha was transient, reaching maximal levels after 30 min and returning to basal levels by 120-300 min. Activation of p42mapk in HUVEC was also observed in response to TNF-alpha or to the protein kinase C (PKC)-activating phorbol ester phorbol 12-myristate 13-acetate (PMA). Pretreatment of HUVEC with IL-1 alpha or TNF-alpha prevented reactivation of p42mapk by either cytokine but did not affect subsequent activation in response to PMA. Activation of p42mapk by PMA was significantly reduced by the PKC inhibitor Ro-31-8220 and completely inhibited by the protein tyrosine kinase inhibitor genistein. Genistein, but not Ro-31-8220, attenuated IL-1 alpha- and TNF-alpha-induced p42mapk activation. Taken together, the results of this study demonstrate 1) that p42mapk is transiently activated in HUVEC by IL-1 alpha and TNF-alpha, 2) that this activation is PKC independent, and 3) that a genistein-inhibitable tyrosine kinase may be an upstream regulator of cytokine-induced p42mapk activation in human endothelium.
Sujet(s)
Endothélium vasculaire/enzymologie , Interleukine-1/pharmacologie , Mitogen-Activated Protein Kinase 1/métabolisme , Facteur de nécrose tumorale alpha/pharmacologie , Catalyse , Cellules cultivées , Endothélium vasculaire/effets des médicaments et des substances chimiques , Activation enzymatique , Antienzymes/pharmacologie , Humains , Inhibiteurs de protéines kinases , 12-Myristate-13-acétate de phorbol/pharmacologieRÉSUMÉ
Vascular endothelial growth factor (VEGF) stimulated a time- and concentration-dependent increase in PGI2 synthesis in human umbilical vein endothelial cells with a mean maximum increase of 2-fold above basal levels at 25 ng/ml after 60 min. VEGF also rapidly stimulated the release of arachidonic acid and phosphorylation and activation of cytosolic phospholipase A2 (cPLA2). The VEGF-related factor, placenta growth factor (PIGF), had little effect on PGI2 synthesis, arachidonic acid release or cPLA2 activation. PD98059, a selective inhibitor of MAP kinase kinase, caused complete inhibition of VEGF-stimulated MAP kinase activity, PGI2 synthesis and cPLA2 gel retardation, but had no effect on VEGF-induced vWF secretion. These findings provide the first evidence that VEGF can stimulate PGI2 synthesis via cPLA2-mediated arachidonic acid release and indicate that VEGF stimulation of this biosynthetic pathway may occur, at least in part, via activation of p42/p44 MAP kinases.
Sujet(s)
Facteurs de croissance endothéliale/pharmacologie , Endothélium vasculaire/métabolisme , Prostacycline/biosynthèse , Lymphokines/pharmacologie , Mitogen-Activated Protein Kinase 1/métabolisme , Mitogen-Activated Protein Kinases , Phospholipases A/métabolisme , Acide arachidonique/métabolisme , Calcium-Calmodulin-Dependent Protein Kinases/métabolisme , Cellules cultivées , Cytosol/enzymologie , Endothélium vasculaire/cytologie , Endothélium vasculaire/enzymologie , Activation enzymatique , Antienzymes/pharmacologie , Flavonoïdes/pharmacologie , Humains , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinase Kinases , Masse moléculaire , Phospholipases A/composition chimique , Phospholipases A2 , Inhibiteurs de protéines kinases , Transduction du signal/physiologie , Veines ombilicales , Facteur de croissance endothéliale vasculaire de type A , Facteurs de croissance endothéliale vasculaireRÉSUMÉ
We have examined the potential role of MAP kinase in the regulation of endothelial cell PG12 synthesis, vWF secretion and E-selectin expression using the specific MEK inhibitor PD98059. PD98059 dose-dependently attenuated the tyrosine phosphorylation and activation of p42 mapk in response to thrombin or inflammatory cytokines. Inhibition of thrombin-induced p42 mapk activation was paralleled by an inhibitory effect of PD98059 on thrombin-driven PG12 generation but not on vWF secretion or IL-1 alpha/TNF alpha-induced E-selectin expression. These results provide evidence for a key role for p42 mapk in the acute regulation of PG12 synthesis in human endothelial cells and suggest that activation of the MAP kinase cascade is not obligatory for cytokine-stimulated E-selectin expression.